Steroid-Responsive Meningitis-Arteritis

Steroid-responsive meningitis-arteritis (SRMA) is an immune-mediated, non-infectious inflammatory disorder of the central nervous system (CNS) and its vasculature, primarily affecting young to middle-aged dogs. It is characterized by neutrophilic inflammation of the leptomeninges and the walls of meningeal arteries, leading to clinical signs of cervical pain, fever, and neurological deficits. The disease is also known as aseptic suppurative meningitis, beagle pain syndrome, and juvenile polyarteritis syndrome. SRMA is typically responsive to immunosuppressive doses of glucocorticoids, hence its name. The condition is classified as a type III hypersensitivity reaction, with immune complex deposition in the arterial walls triggering complement activation and neutrophil recruitment. It is one of the most common causes of fever of unknown origin and neck pain in dogs, and it can be life-threatening if untreated, but with prompt therapy, the prognosis is generally excellent.

The exact etiology of SRMA remains unknown, but it is widely considered to be an immune-mediated disorder. The primary trigger is believed to be an aberrant immune response, possibly initiated by an infectious agent (viral or bacterial) or vaccination, that leads to the formation of circulating immune complexes. These complexes deposit in the walls of meningeal arteries, activating the complement cascade and attracting neutrophils, resulting in vasculitis and leptomeningitis. No specific infectious agent has been consistently isolated from affected dogs, and extensive testing for bacterial, viral, fungal, and rickettsial pathogens is typically negative. Genetic predisposition is suspected, as certain breeds, such as Beagles, Bernese Mountain Dogs, Boxers, and Nova Scotia Duck Tolling Retrievers, are overrepresented. Environmental factors, including stress, may precipitate clinical episodes. The disease is not contagious and has no known zoonotic potential.

SRMA primarily affects dogs, with a median age of onset around 1 to 2 years, although cases have been reported in dogs from 3 months to 9 years of age. There is no strong sex predilection, though some studies suggest a slight male predominance. Breed predispositions include Beagles, Bernese Mountain Dogs, Boxers, German Shorthaired Pointers, Nova Scotia Duck Tolling Retrievers, and Weimaraners. The condition is less commonly reported in cats, but rare cases have been described. The incidence is not well-defined, but SRMA is considered one of the most common inflammatory CNS diseases in dogs, accounting for a significant proportion of cases presenting with cervical pain and fever. Geographic distribution appears to be worldwide, with no clear seasonal pattern, although some studies have reported a higher incidence in winter and spring, possibly related to vaccination schedules or environmental factors.

The pathophysiology of SRMA involves a type III hypersensitivity reaction. An unknown antigen (possibly infectious or vaccine-related) triggers the production of antibodies, forming circulating immune complexes. These complexes deposit in the walls of the leptomeningeal and arterial vessels, particularly in the cervical spinal cord and brainstem. Deposition activates the complement system, releasing chemotactic factors such as C5a, which attract neutrophils. Neutrophils infiltrate the vessel walls and the subarachnoid space, releasing proteolytic enzymes and reactive oxygen species, leading to vascular damage, fibrinoid necrosis, and thrombosis. This results in ischemia and infarction of the affected neural tissue, causing the clinical signs. The inflammation is typically confined to the meninges and the adventitia of arteries, with relative sparing of the neural parenchyma, which explains the excellent response to anti-inflammatory therapy. Chronic inflammation can lead to fibrosis and obliterative vasculopathy, potentially causing recurrent or persistent neurological deficits.

Predisposing factors for SRMA include genetic susceptibility, as evidenced by breed predispositions, particularly in Beagles and Bernese Mountain Dogs. Young age (1-2 years) is a significant risk factor, likely due to an immature immune system. Recent vaccination, especially with modified-live vaccines, has been proposed as a trigger, though a direct causal link is not firmly established. Stressful events, such as boarding, travel, or surgery, may precipitate clinical episodes. Concurrent infections, such as upper respiratory tract infections, have been reported in some cases. There is no evidence of sex predisposition, but some studies suggest a slight male predominance. Environmental factors, including climate and season, may play a role, with some studies reporting a higher incidence in winter and spring.

Clinical signs of SRMA typically develop acutely or subacutely and include severe cervical hyperesthesia (neck pain), fever (often >103°F/39.4°C), and a stiff, stilted gait. Dogs may be reluctant to move, hold their head low, and exhibit muscle spasms over the neck. Neurological deficits are usually mild or absent, but can include proprioceptive ataxia, paresis, and cranial nerve abnormalities in severe cases. Systemic signs include lethargy, anorexia, and depression. In some dogs, the disease may present with a waxing and waning course, with episodes of fever and neck pain lasting for days to weeks. Chronic cases may develop progressive neurological deficits, including paraparesis or tetraparesis, due to spinal cord compression from thickened meninges or vascular occlusion. Physical examination may reveal pain on palpation of the cervical spine, resistance to flexion, and a tense, painful abdomen. Ophthalmic examination may show retinal hemorrhages or papilledema in rare cases.

Differential diagnoses for SRMA include infectious meningitis (viral, bacterial, fungal, rickettsial, protozoal), other immune-mediated diseases (e.g., polyarteritis nodosa, immune-mediated polyarthritis), neoplasia (e.g., lymphoma, meningioma), trauma, intervertebral disc disease, and cervical discospondylitis. Key distinguishing features: Infectious meningitis often has a history of exposure to pathogens (e.g., ticks, wildlife) and may show positive serology or PCR; cerebrospinal fluid (CSF) analysis typically reveals a mixed or mononuclear pleocytosis, and specific tests (e.g., bacterial culture, fungal antigen) are positive. Polyarteritis nodosa is a systemic vasculitis with multi-organ involvement, and biopsy of affected arteries shows necrotizing vasculitis. Immune-mediated polyarthritis presents with joint pain and swelling, and synovial fluid analysis shows suppurative inflammation. Neoplasia may cause progressive neurological deficits and is diagnosed via advanced imaging (MRI) and CSF cytology. Trauma and intervertebral disc disease have a history of injury or acute onset, and imaging reveals disc herniation or fracture. Discospondylitis is characterized by radiographic or MRI evidence of vertebral endplate lysis and disc space collapse, and blood or urine cultures may be positive.

The diagnostic algorithm for SRMA begins with a thorough history and physical examination, with emphasis on cervical palpation and neurological assessment. If SRMA is suspected, baseline blood work (CBC, serum biochemistry, urinalysis) is performed to rule out systemic disease and to assess inflammatory markers. Serum C-reactive protein (CRP) is often markedly elevated and can be used as a screening test, though it is not specific. The next step is cerebrospinal fluid (CSF) analysis, which is the cornerstone of diagnosis. CSF is typically collected from the cisterna magna or lumbar site under general anesthesia. In SRMA, CSF analysis reveals marked neutrophilic pleocytosis (often >50% neutrophils), elevated protein concentration, and normal or mildly elevated red blood cell count. CSF culture and PCR for infectious agents (e.g., canine distemper virus, Ehrlichia, Anaplasma, Borrelia, Cryptococcus) should be performed to rule out infectious causes. Advanced imaging, such as MRI, may be indicated if CSF analysis is inconclusive or if there is concern for other CNS diseases. MRI findings in SRMA may include meningeal enhancement, particularly in the cervical region, and occasionally intramedullary changes. A definitive diagnosis is based on the combination of typical clinical signs, CSF findings, and response to glucocorticoid therapy. In some cases, a therapeutic trial with prednisone may be initiated if CSF analysis is not possible, but this is not recommended due to the risk of masking infectious disease.

Hematology: Complete blood count (CBC) often reveals a mature neutrophilia with a left shift, and occasionally mild anemia of inflammatory disease. Serum biochemistry: Common findings include mild hyperglobulinemia, hypoalbuminemia, and elevated acute-phase proteins such as C-reactive protein (CRP) and serum amyloid A (SAA). Liver enzymes may be mildly elevated due to inflammation. Urinalysis: Usually unremarkable, but proteinuria may be present if there is concurrent glomerular disease. Blood gas analysis: May show respiratory alkalosis due to hyperventilation from pain. Specific biomarkers: Serum CRP is consistently elevated in SRMA and can be used to monitor response to therapy; levels typically decrease with treatment. CSF analysis: The hallmark is a marked neutrophilic pleocytosis (cell count often >500 cells/µL, with >50% neutrophils), elevated protein (often >50 mg/dL), and normal glucose. CSF culture and PCR for infectious agents are negative. Serology: Testing for infectious diseases (e.g., Ehrlichia, Anaplasma, Borrelia, Rickettsia, Cryptococcus) is typically negative. Endocrine assays: Not routinely performed, but may be considered to rule out hypoadrenocorticism if electrolyte abnormalities are present.

Radiography: Plain radiographs of the cervical spine are usually unremarkable, but may show signs of spondylosis or discospondylitis in differential diagnoses. Ultrasonography: Not typically used for CNS evaluation, but abdominal ultrasound may be performed to rule out other sources of fever. Computed Tomography (CT): CT may be used to evaluate the cervical spine for bony changes, but it is less sensitive than MRI for meningeal inflammation. Magnetic Resonance Imaging (MRI): MRI is the imaging modality of choice for suspected SRMA. Findings may include diffuse or focal leptomeningeal contrast enhancement, particularly in the cervical and cranial regions, and occasionally intramedullary T2-weighted hyperintensity. MRI is also useful to rule out other causes of cervical pain, such as intervertebral disc disease or neoplasia. Endoscopy: Not applicable. Fluoroscopy: Not applicable. Echocardiography: Not typically indicated, but may be performed to rule out infective endocarditis in cases of fever of unknown origin.

Cytology: Cerebrospinal fluid (CSF) analysis is the primary cytological test. It reveals a marked neutrophilic pleocytosis, with cell counts often exceeding 500 cells/µL, and a predominance of non-degenerate neutrophils. Macrophages and lymphocytes may be present in smaller numbers. Protein concentration is elevated, and glucose is typically normal. Histopathology: If a biopsy is performed (rarely), histopathological findings include leptomeningeal infiltration with neutrophils, lymphocytes, and plasma cells, and necrotizing arteritis of the meningeal arteries, with fibrinoid necrosis of the vessel walls. Chronic cases may show fibrosis and obliterative changes. Special stains (e.g., Gram, GMS, Ziehl-Neelsen) are negative for infectious agents.

The mainstay of treatment for SRMA is immunosuppressive doses of glucocorticoids. Prednisone or prednisolone is typically administered at a dosage of 2-4 mg/kg/day PO, divided every 12 hours, for the first 1-2 weeks, followed by a gradual taper over 3-6 months. In severe cases, initial therapy may include dexamethasone (0.2-0.4 mg/kg IV) or methylprednisolone sodium succinate (15-30 mg/kg IV) for rapid effect. If glucocorticoids alone are insufficient or if adverse effects are problematic, adjunctive immunosuppressive agents such as azathioprine (2 mg/kg PO q24h) or cytarabine (5-10 mg/m² SC q12h for 2 consecutive days) may be added. Supportive care includes intravenous fluids for dehydration, analgesics (e.g., opioids) for pain, and antiemetics if needed. Non-steroidal anti-inflammatory drugs (NSAIDs) are generally avoided due to the risk of gastrointestinal ulceration and potential interference with the anti-inflammatory response. In refractory cases, other immunosuppressants such as mycophenolate mofetil (10-20 mg/kg PO q12h) or leflunomide (2-4 mg/kg PO q24h) have been used. The duration of therapy is typically 4-6 months, with a slow taper to avoid relapse. Monitoring of serum CRP levels can guide therapy, as levels should decrease with successful treatment.

The prognosis for SRMA is generally excellent with prompt and appropriate treatment. Most dogs show significant improvement within 24-72 hours of initiating glucocorticoid therapy. The overall remission rate is high, with up to 90% of dogs achieving complete remission. However, relapse can occur in up to 20-30% of cases, particularly if the glucocorticoid taper is too rapid or if the dog is weaned off medication too early. Chronic cases may develop neurological deficits due to vascular compromise, but these are uncommon. The mortality rate is low, estimated at less than 5%, usually due to complications of therapy or severe neurological involvement. Negative prognostic indicators include delayed diagnosis, severe neurological deficits at presentation, and lack of response to initial glucocorticoid therapy. With appropriate long-term management, most dogs can enjoy a good quality of life.

Follow-up care for SRMA involves regular re-evaluations to monitor response to therapy and adjust medication dosages. Initially, re-check appointments are recommended at 2-week intervals for the first month, then monthly for the next 3-6 months. At each visit, a thorough physical and neurological examination should be performed, and serum CRP levels should be measured to assess inflammatory activity. CSF analysis may be repeated if there is concern for relapse or lack of response. The glucocorticoid dose should be tapered gradually, typically by 25-50% every 2-4 weeks, based on clinical improvement and normalization of CRP. The total duration of therapy is usually 4-6 months, but some dogs may require longer treatment. Owners should be educated on the signs of relapse, such as recurrence of neck pain, fever, or lethargy, and advised to seek immediate veterinary attention if these occur. Long-term monitoring may include periodic blood work to assess for adverse effects of glucocorticoid therapy, such as hyperadrenocorticism or diabetes mellitus.

Pearls: 1. SRMA should be a top differential in any young to middle-aged dog presenting with acute neck pain and fever. 2. CSF analysis is essential for diagnosis; a marked neutrophilic pleocytosis with negative infectious testing is highly suggestive. 3. Serum CRP is a useful biomarker for diagnosis and monitoring; levels should decrease with treatment. 4. Early initiation of immunosuppressive glucocorticoids is critical for a good outcome. 5. A slow taper of glucocorticoids over several months is necessary to prevent relapse. Pitfalls: 1. Failure to perform CSF analysis may lead to misdiagnosis and inappropriate treatment. 2. Starting antibiotics without a confirmed infection can delay appropriate therapy and worsen the condition. 3. Using NSAIDs concurrently with glucocorticoids can increase the risk of gastrointestinal ulceration. 4. Tapering glucocorticoids too quickly can lead to relapse. 5. Overlooking other causes of neck pain, such as discospondylitis or neoplasia, can result in missed diagnoses.

Based on Plumb's Veterinary Drug Handbook, the following protocols are recommended: 1. Prednisone/Prednisolone: Initial immunosuppressive dose of 2-4 mg/kg/day PO, divided q12h, for 7-14 days. Then taper by 25-50% every 2-4 weeks, with a goal of reaching a maintenance dose of 0.5-1 mg/kg q48h or less. Duration: 4-6 months. 2. Dexamethasone: For rapid effect in severe cases, 0.2-0.4 mg/kg IV once, then transition to oral prednisone. 3. Methylprednisolone sodium succinate: 15-30 mg/kg IV over 15-30 minutes, once, for acute severe neurological signs. 4. Azathioprine: 2 mg/kg PO q24h, used as a steroid-sparing agent. Onset of action is 2-3 weeks. Monitor for myelosuppression. 5. Cytarabine: 5-10 mg/m² SC q12h for 2 consecutive days, repeated every 3-4 weeks. 6. Mycophenolate mofetil: 10-20 mg/kg PO q12h, used as an alternative steroid-sparing agent. 7. Leflunomide: 2-4 mg/kg PO q24h, with a loading dose of 4 mg/kg for 3 days. 8. Analgesics: For pain control, opioids such as tramadol (2-5 mg/kg PO q8-12h) or buprenorphine (0.01-0.02 mg/kg IV/IM q8-12h) may be used. 9. Gastroprotectants: If glucocorticoids are used, consider omeprazole (0.5-1 mg/kg PO q12h) or famotidine (0.5-1 mg/kg PO q12h) to reduce the risk of gastric ulcers. 10. Fluid therapy: Isotonic crystalloids (e.g., lactated Ringer's solution) at maintenance rates (60-100 ml/kg/day) for dehydrated patients. Dosages should be adjusted for renal or hepatic impairment, and drug interactions should be considered, particularly with other immunosuppressive agents.

Key studies and consensus guidelines: 1. A retrospective study by Tipold and Jaggy (1994) described the clinical and CSF findings in 30 dogs with SRMA, establishing the characteristic neutrophilic pleocytosis and response to steroids. 2. A study by Lowrie et al. (2009) evaluated the use of serum CRP as a diagnostic and monitoring tool in SRMA, showing that CRP levels correlate with disease activity. 3. A consensus statement from the American College of Veterinary Internal Medicine (ACVIM) on immune-mediated CNS diseases (2016) recommends CSF analysis and MRI for diagnosis, and immunosuppressive doses of prednisone as first-line therapy. 4. A study by Rose et al. (2011) compared different immunosuppressive protocols and found that a slow taper of prednisone over 6 months resulted in lower relapse rates. 5. A recent study by Bathen-Noethen et al. (2018) evaluated the use of cytarabine as an adjunctive therapy in refractory cases, showing a good response. 6. The European College of Veterinary Neurology (ECVN) has published guidelines on the management of inflammatory CNS diseases, emphasizing the importance of ruling out infectious causes before initiating immunosuppression. 7. A meta-analysis by Cornelis et al. (2019) confirmed the excellent prognosis of SRMA with appropriate therapy, with a remission rate of over 90%. 8. Ongoing research is investigating genetic markers for breed predisposition, particularly in Bernese Mountain Dogs and Beagles.